TYRA Stock Overview
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Tyra Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.00 |
| 52 Week High | US$20.67 |
| 52 Week Low | US$10.38 |
| Beta | 1.12 |
| 1 Month Change | -2.85% |
| 3 Month Change | 19.85% |
| 1 Year Change | 33.44% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -38.46% |
Recent News & Updates
Recent updates
We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate
Jan 13
We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth
Sep 27Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Jun 13Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Feb 23Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Nov 09Tyra Biosciences GAAP EPS of -$0.36
Aug 04Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
Jul 21Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
Mar 31Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth
Dec 15Shareholder Returns
| TYRA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.7% | 1.0% | 1.2% |
| 1Y | 33.4% | 0.7% | 24.9% |
Return vs Industry: TYRA exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: TYRA exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| TYRA volatility | |
|---|---|
| TYRA Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TYRA has not had significant price volatility in the past 3 months.
Volatility Over Time: TYRA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 49 | Todd Harris | tyra.bio |
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors.
Tyra Biosciences, Inc. Fundamentals Summary
| TYRA fundamental statistics | |
|---|---|
| Market cap | US$860.34m |
| Earnings (TTM) | -US$69.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-12.2x
P/E RatioIs TYRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TYRA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$69.13m |
| Earnings | -US$69.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.32 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TYRA perform over the long term?
See historical performance and comparison